دورية أكاديمية
Macrolide Therapy Decreases Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis
| العنوان: | Macrolide Therapy Decreases Chronic Obstructive Pulmonary Disease Exacerbation: A Meta-Analysis |
|---|---|
| المؤلفون: | Yao, Guo-Yan, Ma, Yan-Liang, Zhang, Mo-Qin, Gao, Zhan-Cheng |
| المساهمون: | Ma, YL (reprint author), Peking Univ, Peoples Hosp, Dept Resp & Crit Care Med, 11 Xizhimen South St, Beijing 100044, Peoples R China., Peking Univ, Peoples Hosp, Dept Resp & Crit Care Med, Beijing 100044, Peoples R China., Beijing Fengtai Hosp, Dept Resp Med, Beijing, Peoples R China., Peking Univ, Peoples Hosp, Dept Resp & Crit Care Med, 11 Xizhimen South St, Beijing 100044, Peoples R China. |
| المصدر: | PubMed ; SCI |
| بيانات النشر: | respiration |
| سنة النشر: | 2013 |
| المجموعة: | Peking University Institutional Repository (PKU IR) / 北京大学机构知识库 |
| مصطلحات موضوعية: | Chronic obstructive pulmonary disease, Exacerbation, Macrolide, Meta-analysis, LONG-TERM, DIFFUSE PANBRONCHIOLITIS, ERYTHROMYCIN, COPD, AZITHROMYCIN, ANTIBIOTICS, FLUTICASONE, PREVENTION, SALMETEROL, SURVIVAL |
| الوصف: | Background: Macrolide antibiotics have anti-inflammatory effects, and long-term administration may reduce chronic obstructive pulmonary disease (COPD) exacerbations. Objective: To investigate the effects of long-term treatment of macrolide therapy for COPD. Methods: We searched the PubMed and Embase databases to identify randomized controlled trials that evaluated the effect of macrolide therapy (of at least 2 weeks) for COPD. The primary outcome assessed was the frequency of acute exacerbations during follow-up. Results: Six trials involving 1,485 COPD patients were included in the analysis. Analysis of the pooled data of all 6 trials showed that macrolide administration reduced the frequency of acute exacerbations of COPD [risk ratio (RR) = 0.62; 95% CI 0.43-0.89, p = 0.01]. Subgroup analysis showed that only erythromycin might be associated with decreased COPD exacerbations (erythromycin: p = 0.04, azithromycin: p = 0.22, clarithromycin: p = 0.18). Moreover, macrolide therapy for 3 months did not significantly reduce the number of exacerbations (p = 0.18), whereas a beneficial effect was conclusive in the 6-month (p = 0.009) and 12-month (p = 0.03) treatment subgroups. In addition, nonfatal adverse events were more frequent in the macrolide treatment groups than in the controls (RR = 1.32; 95% CI 1.06-1.64, p = 0.01). However, related clinical factors had no influence on the overall result (p = 0.19). There was no publication bias among the included trials. Conclusions: Macrolide therapy was effective and safe in decreasing the frequency of exacerbations in patients with COPD. Treatment might provide a significant benefit but only when therapy lasts more than 6 months. Copyright (C) 2013 S. Karger AG, Basel ; http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000324694300014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701Test ; Respiratory System ; SCI(E) ; PubMed ; 5 ; REVIEW ; 3 ; 254-260 ... |
| نوع الوثيقة: | journal/newspaper |
| اللغة: | English |
| تدمد: | 0025-7931 |
| العلاقة: | RESPIRATION.2013,86,(3),254-260.; 656564; http://hdl.handle.net/20.500.11897/307127Test; WOS:000324694300014 |
| DOI: | 10.1159/000350828 |
| الإتاحة: | https://doi.org/20.500.11897/307127Test https://doi.org/10.1159/000350828Test https://hdl.handle.net/20.500.11897/307127Test |
| رقم الانضمام: | edsbas.C133D5FC |
| قاعدة البيانات: | BASE |
| تدمد: | 00257931 |
|---|---|
| DOI: | 10.1159/000350828 |